Petlife Pharmaceuticals, Inc.
PTLF · OTC
2/28/2018 | 11/30/2017 | 8/31/2017 | 5/31/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -396.71% | -36.08% | 0.00% | -8.76% |
| EV / EBITDA | -2.42 | -2.69 | -0.46 | -2.46 |
| Quality | ||||
| ROIC | 15.59% | 18.80% | 258.18% | 117.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.38 | 0.26 | -0.06 | 0.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -35.44% | -204.95% | 221.85% | 40.22% |
| Safety | ||||
| Net Debt / EBITDA | -2.30 | -1.82 | -0.46 | -1.08 |
| Interest Coverage | -4.14 | -2.22 | -4.69 | -145.28 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |